/PRNewswire/ Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies long-term.
The Series A round was co-led by Novartis Venture Fund and Sofinnova Partners and has seen participation from Pfizer Ventures, Mission BioCapital, Gimv, Pureos, Bristol Myers Squibb, Eli
/PRNewswire/ Mediar Therapeutics Inc., a biotechnology company advancing a portfolio of first-in-class therapies that halt and even reverse the course of.
ImmunOs Therapeutics Raises $74 Million Series B Financing Round streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.